<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032404</url>
  </required_header>
  <id_info>
    <org_study_id>PROT002 - Test Plan 01 Rev A</org_study_id>
    <nct_id>NCT05032404</nct_id>
  </id_info>
  <brief_title>Blue Note Therapeutics Product BNT 103 Usability and User Engagement</brief_title>
  <official_title>BNT 103 Usability and User Engagement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blue Note Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Healthcare Innovation Technology Lab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Blue Note Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This test aims to explore product development-focused usability and user engagement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sponsor is testing an innovative peer-to-peer communication tool during this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 26, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients</measure>
    <time_frame>Baseline up to Week 7</time_frame>
    <description>Higher scores indicate higher ease of use / easier to use applications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Current Status - Anxiety (MOCS-A)</measure>
    <time_frame>Baseline up to Week 7</time_frame>
    <description>The MOCS-A is a 13-item self-report measure developed to assess participants' current self-perceived status on: the ability to relax at will, recognize stress-inducing situations, restructure maladaptive thoughts, be assertive about needs, and choose appropriate coping responses as needed, higher scores indicate greater self-perceived proficiency with these skills.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>BNT103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive BNT103. BNT103 provides 10 sessions over approximately 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BNT103</intervention_name>
    <description>BNT-103â„¢ is a prescription digital therapeutic specifically designed to treat the symptoms of anxiety and depression related to cancer. There are 10 sessions provided over approximately 10 weeks.</description>
    <arm_group_label>BNT103</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient can read, write, and speak in English&#xD;
&#xD;
          -  Patient is between the ages of 35-55&#xD;
&#xD;
          -  Diagnosed with Stage I-III breast cancer&#xD;
&#xD;
          -  In active treatment or within 3 months of ending active treatment and under the care&#xD;
             of a clinician at time of study&#xD;
&#xD;
          -  Apple mobile phone or tablet user&#xD;
&#xD;
          -  Willing to participate in study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any participant not meeting inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Diagnosed with breast cancer</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dianne Shumay, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blue Note Therapeutics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blue Note Therapeutics</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Antoni MH, Lechner S, Diaz A, Vargas S, Holley H, Phillips K, McGregor B, Carver CS, Blomberg B. Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun. 2009 Jul;23(5):580-91. doi: 10.1016/j.bbi.2008.09.005. Epub 2008 Sep 20.</citation>
    <PMID>18835434</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

